Valuation: Pluristem Therapeutics Inc.

Market Cap 12.22M 10.92M 10.19M 9.25M 17.43M 1.18B 17.56M 122M 47.83M 601M 45.88M 44.89M 1.93B P/E 2025
-1.39x
P/E 2026 -0.85x
Enterprise Value 39.33M 35.14M 32.79M 29.78M 56.09M 3.8B 56.51M 394M 154M 1.93B 148M 144M 6.22B EV / Sales 2025
39,078,124x
EV / Sales 2026 48,878,101x
Free-Float
57.48%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer 54 29/03/2017
Director of Finance/CFO 42 01/12/2022
Chief Operating Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 54 01/02/2015
Director/Board Member 56 06/01/2021
Director/Board Member 64 01/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
+11.70%-24.18% - - 12.22M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-1.16%+23.36%+79.34% 58.81B
+0.17%-1.16%+3.59%+34.55% 48.45B
+0.50%-2.14%+331.33%+688.65% 42.84B
-0.72%-3.99%+28.50%+29.35% 42.79B
+0.34%-0.52%+6.56%+110.67% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
-0.50%-3.10%-10.19%-12.86% 24.05B
Average +1.23%-0.25%+52.97%+122.53% 43.81B
Weighted average by Cap. +0.53%-0.54%+55.85%+128.90%

Financials

2025 2026
Net sales 1.34 1.19 1.11 1.01 1.91 129.24 1.92 13.38 5.23 65.73 5.02 4.91 211.29 1.02 0.91 0.85 0.77 1.45 98.28 1.46 10.18 3.98 49.98 3.81 3.73 160.68
Net income -22.58M -20.18M -18.83M -17.1M -32.2M -2.18B -32.44M -226M -88.38M -1.11B -84.78M -82.95M -3.57B -23.82M -21.28M -19.86M -18.04M -33.97M -2.3B -34.22M -239M -93.23M -1.17B -89.43M -87.49M -3.77B
Net Debt 13.44M 12.01M 11.2M 10.17M 19.16M 1.3B 19.3M 135M 52.59M 661M 50.45M 49.35M 2.13B 27.11M 24.22M 22.6M 20.53M 38.66M 2.62B 38.95M 272M 106M 1.33B 102M 99.58M 4.29B
Logo Pluristem Therapeutics Inc.
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Employees
-